34.70
+3.89%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genetics Generation Advancement
Its shares trade on Taipei Exchange under the ticker 4160.TWO. It has been listed since 15 July 2011. In the fiscal year to 31 December 2025, it reported revenue of TWD 603.1m and net income of TWD 21.4m. At that date it held total assets of TWD 806.1m and shareholders' equity of TWD 601.6m.
Genetics Generation Advancement Corp. engages in the provision of genetic testing, molecular diagnostics, biotechnology services, personal health-related testing services, biological information services, and health care services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-07-15. The firm mainly provides genetic testing, molecular diagnostics, biotechnology, personalized medical related testing, biological information and health care services. The firm mainly serves in the areas of maternal-fetal precision, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection and precision health management. The firm operates its businesses in domestic market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Jul 2011
- Employees
- 3
- Website
- gga.asia ↗
Leadership
Pay as last reported
- Mr. Handong ZhangChairman of the Board, since 2008
- Yuchun XiaoManager of Finance & Accounting
- Taisheng ZhangChief Technology Officer
- Mr. Qingyuan KangGeneral Manager
- Yuchun LiuExecutive Deputy General Manager
- Xiuhui WangDeputy General Manager-Business Division
- Fangchun HuangCorporate Governance Officer
- Yuming LiangDirector
- Mr. Wenzheng ZhangDirector
- Yingbin ZhengDirector
- Peijun ChenIndependent Director
- Mr. Yujun HongIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company provides genetic testing and molecular diagnostics services to clients.
- Maternal-fetal precision testing is a key service offered by the firm.
- Non-invasive cancer detection capabilities are part of the business portfolio.
Weaknesses
- The firm has only three employees working in the organization.
- Operations are limited to domestic and overseas markets without expansion.
- Biotechnology services rely on a very small workforce for execution.
Opportunities
- Personal health-related testing services can attract more individual customers globally.
- Pediatric disease diagnosis services offer potential growth in healthcare sectors.
- Drug-associated diagnosis services may expand within the biotechnology industry.
Threats
- Small workforce size may limit the ability to serve overseas markets.
- Reliance on biological information services creates vulnerability in data management.
- Health care services face competition from larger established biotech firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.